

**THE AMENDMENTS**

**In the Claims**

1. (Previously Amended) A method for purifying and concentrating AAV-2 and antigen portions thereof from a sample, said method comprising the steps of:  
binding AAV-2 or antigen portions thereof to an activated chromatographic material which comprises antibodies linked thereto and directed against AAV-2, and  
eluting said AAV-2 or antigen portions thereof using a solution containing ~~0.5 to 4.5~~ 2-3 M  $\text{MgCl}_2$ .
2. (Previously Amended) The method according to claim 1, wherein said AAV-2 is a wild-type AAV-2 or a recombinantly prepared AAV-2.
3. (Original) The method according to claim 1 or 2, wherein the chromatographic material is selected from the group consisting of agarose gels, dextran gels, cellulose gel matrices and acrylamide gel matrices.
4. (Previously Amended) The method according to claim 1 or 2, wherein the chromatographic material carries a ligand suitable for binding proteins.
5. (Previously Amended) The method according to claim 3, wherein the chromatographic material is CNBr-activated agarose or NHS-activated agarose.
6. (Cancelled).
7. (Previously Amended) The method according to claim 1 or 2, wherein the sample containing the AAV-2 is a cell culture supernatant or cell extracts.
8. (Previously Amended) The method according to claim 1 or 2, wherein the antibody directed against AAV-2 is DSM ACC2194.

9. (Previously Amended) A kit for carrying out the method according to claims 1 or 2, comprising
- an antibody directed against AAV-2, and
  - conventional auxiliary agents selected from the group consisting of buffers, chromatographic material and controls.